Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01952132 | Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects | PHASE2 | COMPLETED | 40 | — | — | Sep 1, 2013 | Apr 1, 2014 | Oct 22, 2018 | 1 | United States |
Incidence of adverse events
| Arm | Type | Description |
|---|---|---|
| OMS643762 Low Dose | EXPERIMENTAL | Orally administering OMS643762 low dose daily for 14 days |
| OMS643762 High Dose | EXPERIMENTAL | Orally administering OMS643762 high dose daily for 14 days |
| Placebo | PLACEBO_COMPARATOR | Orally administering placebo daily for 14 days |
| OMS643762 Medium Dose | EXPERIMENTAL | Orally administering OMS643762 medium dose daily for 14 days |
| Name | Type | Description |
|---|---|---|
| OMS643762 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Competent to provide informed consent. * Voluntarily provide informed consent and Health Insurance Portability and Accounting Act (HIPAA) Authorization in accordance with local regulations and governing Institutional Review Board (IRB) requirements prior to any procedures or e...